News | August 22, 2013

Michigan Tech Professor Probes Hypertension, Congestive Heart Failure

Qinghui Chen looks to decipher an elusive component with both diseases

August 22, 2013 — Qinghui Chen, assistant professor in Michigan Tech’s kinesiology and integrative physiology department, wants to get to the bottom of two cardiovascular diseases: hypertension and congestive heart failure.

Hypertension is high blood pressure, which contributes to stroke, heart failure and kidney failure. Congestive heart failure is the weakening and inability of the heart to supply sufficient blood flow to meet the needs of the body.

Both are chronic and dangerous — and common worldwide: up to 10 percent of people over age 65 experience congestive heart failure; up to 25 percent are affected by hypertension.

There is an elusive component with both diseases: they agitate the central nervous system, but it is unknown how. Chen says his goal is to decipher these neural mechanisms.

“We know there’s a neural part of these two diseases,” he said, “but we don’t completely understand what’s going on. There’s a gap in the science.”

Exercise also induces significant changes of neural activity, and Chen addresses the role of exercise in mediating the two diseases. “This is important work,” he said. “If we can identify the mechanism, then we can develop a treatment.”

Chen has gone from the clinician to the scientist. He went to medical school in China, then earned a Ph.D. in cardiovascular physiology in Japan, focusing on figuring out the central nervous mechanism of cardiovascular disease.

He came to Tech in 2010 from the University of Texas in San Antonio. In 2009, he received the Recognition Award for Meritorious Research by the Central Nervous Section of the American Physiological Society.

For more information: www.mtu.edu

Related Content

St. Bartholomew's Hospital Initiates CALM-2 Hypertension Trial
News | Hypertension | February 20, 2019
California-based Vascular Dynamics Inc. (VDI) is sponsoring a new clinical trial, called CALM-2 (Controlling And...
Research Sheds Light on Blood Pressure Drug Function
News | Hypertension | January 31, 2019
Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target of widely...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Hypertension | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Barbershop Intervention Continues to Lower Blood Pressure at One Year
News | Hypertension | December 27, 2018
African-American men participating in a blood pressure reduction program implemented in barbershops continued to have...
Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension
News | Hypertension | December 14, 2018
Digital health company Analytics 4 Life and Actelion Pharmaceuticals Ltd. announced a collaborative agreement to...
Hypertensive Crisis Five Times More Likely Among Blacks, according to a late-breaking study at AHA 2018. #AHA #AHA18 #AHA2018
News | Hypertension | November 13, 2018
Black adults experience dangerous spikes in high blood pressure, called a hypertensive crisis, at a rate that is five...
Home Monitoring Confirms Clinic Diagnosis of High Blood Pressure
News | Hypertension | October 29, 2018
Blood pressure readings of 130/80 millimeters of mercury (mmHg) or higher taken at home can be used to diagnose...
 Pulmonary artery denervation for CpcPH from the PADN-5 trial. #TCT2017

A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.

News | Hypertension | October 04, 2018
October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and
BackBeat Cardiac Neuromodulation Therapy Reduces Blood Pressure at Two Years
News | Hypertension | October 02, 2018
Two-year results of the Moderato I Study demonstrated immediate, substantial and sustained reduction in blood pressure...
Overlay Init